Board summary
Key figures
43,533
Registered population
89.0% aged 18–64
3.7%
Aged 65+
ICB 14.9% · England 17.9%
33.9%
Ethnic minority (non-White)
14.7% Asian · England 9.6%
20.0%
In IMD quintile 1
ICB 40.7% · England 21.0%
~7,012
Core20 residents (est.)
Resident basis; registered basis ~8,776 · see page 3
2,174
Hypertension register
-2.07% in 3 yrs · England +5.60%
449
SMI register
4.7% of Manchester (LAD)'s
492
COPD register
Reviews +16.40% in 3 yrs
Forecast to 2030
2,222
Hypertension patients, 2030
+48 on today
80.0%
QRISK ≥20% on statins, 2030
+3.10pp over 3 yrs
1.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma reviews and high prescribing.
With 66.4% of 1,680 asthma patients reviewed, about 560 (564) lack a review alongside 3,341 items per 1,000 aged 5–19 (England 1,488).
Pre-school booster coverage trails target.
Age-5 4-in-1 booster coverage in Q1 2025/26 is 77.4% across 31 children (ICB 80.5%, England 80.9%), 17.6 pp below the 95.0% target.
Lipid therapy and BP recording.
Lipid therapy reaches 73.3% for QRISK ≥ 20% (England 63.6%) and 84.5% for CKD (England 70.3%), with 92.5% hypertension BP recording.
Population, age and ethnicity
Working-age patients make up 89.0% of the list, which may shape low crude prevalence
Across 43,533 registered patients, 89.0% are aged 18–64, exceeding Manchester (68.9%), the ICB (63.3%) and England (62.7%). Conversely, 3.7% (1,620 patients) are aged 65+, below Manchester (9.6%), the ICB (14.9%) and England (17.9%). Children aged 0–17 comprise 7.2% (Manchester 21.4%, ICB 21.8%, England 19.6%). Census resident estimates show 66.1% White (Manchester 56.8%, ICB 76.4%, England 81.1%), alongside 14.7% Asian and 8.5% Black residents. Unverified projections suggest 3.7% list growth to 2030 (Manchester 2.6%, ICB 1.6%, England 2.3%). This younger demographic may explain low crude disease prevalence, though resident ethnicity does not reflect registered patients directly.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Manchester LA) | 2,357 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.9% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.2% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Manchester LA) | 1,281 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Manchester LA) | 26.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
A 20.0% PCN Core20 share masks a 27.5 pp spread across practices
The PCN Core20 share is 20.0%, below Manchester (59.8%), the ICB (40.7%) and England (21.0%). Across practices, a 27.5 pp spread separates New Islington Medical Centre (31.8%, 4,158 estimated patients) and Ancoats Urban Village Medical Practice (27.3%, 3,924 estimated patients) from City Health Centre (4.3%, 694 estimated patients). Summed practice estimates of 8,776 registered patients diverge from the PCN resident deciles 1 and 2 count of 7,012. Proactive outreach should prioritise New Islington Medical Centre and Ancoats Urban Village Medical Practice, where deprivation is concentrated by both share and volume.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
449
SMI register
1.09% recorded prevalence
81
Learning disability register
0.20% recorded prevalence
2
Care homes, 115 beds
In the PCN catchment
8.7%
Provide unpaid care
Manchester (LAD), Census 2021
The PCN records 449 patients on the severe mental illness register (1.1%, Manchester 1.3%, England 1.0%) and 81 with learning disabilities (0.2%, England 0.6%). Catchment care homes contain 115 beds across 2 sites, though resident registrations are unconfirmed. The 449 patients on the severe mental illness register represent a larger cohort than the 81 patients recorded for learning disability.
Severe mental illness: physical health checks
Across 449 severe mental illness patients, 81.8% received a blood pressure check (England 83.4%), with City Health Centre at 74.7%, and 82.0% had BMI recorded (England 82.1%). Over three years, blood pressure check coverage rose 1.5 pp (England +4.4 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
2,174
Hypertension register
−2.07%
Register growth, 3 yrs
Manchester (LAD) +4.49% · England +5.60%
+2.14pp
BP control, under 80
≤140/90 · −0.01pp aged 80+
+48
More patients by 2030
Forecast 2,222 (5.08%)
Hypertension case-finding and control
The PCN records 2,174 patients on its hypertension register, an unadjusted crude prevalence of 5.3% that is below Manchester (10.5%), the ICB (14.4%) and England (15.2%), with three-year prevalence falling 2.1% (England +5.6%). While 92.5% of recorded patients have a recent blood pressure check (England 90.0%), control to target in patients aged under 80 is 66.1% (England 67.8%), ranging from 65.1% at Ancoats Urban Village Medical Practice and 65.6% at City Health Centre to 68.1% at New Islington Medical Centre.
Lipids and statins
Lipid-lowering therapy coverage is strong across primary prevention groups: 73.3% of patients with QRISK ≥ 20% receive therapy against 63.6% in England, and CKD coverage reaches 84.5% against 70.3%.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 29,885 | £2.00 | £1.94 | £1.86 | £59,770 |
| Cardiovascular (all), 2025 | 39,176 | £2.72 | £3.15 | £3.33 | £106,559 |
Across 29,885 lipid-regulating drug items prescribed in 2026, the PCN averaged £2.00 per item, compared to £1.86 in England, £1.94 in the ICB, and £2.21 in Manchester (LAD). This unit-cost difference represents £4,184 more than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+14.46%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.90%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 4.2% (1,680 patients) against England's 6.6%, with 66.4% reviewed in the last 12 months (England 65.7%), leaving an estimated 564 patients without a review. Prescribing reached 3,341 asthma management items per 1,000 aged 5-19 (England 1,488; Manchester 1,697). The COPD register includes 492 patients (1.2% prevalence vs England 1.9%), with three-year prevalence falling 5.2% (England +2.6%), while 80.3% were reviewed (England 76.4%).
Cancer register and children's immunisation
Cancer prevalence is 1.2% (503 patients) against England's 3.8% and Manchester's 2.2%. Among 3,155 registered children aged 0-17, immunisation coverage trails England and the 95.0% target: 6-in-1 at 12 months is 85.7% (England 91.0%), MMR dose 1 at 24 months is 83.0% (England 88.3%), and 4-in-1 at age 5 is 77.4% (England 80.9%), which is 17.6 pp below the 95.0% target.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In NHS Greater Manchester ICB, 55.6% of cancers with a known stage (6,491 of 11,679 staged cancers; 70.8% known-stage share across 16,492 cancers in 2022) were diagnosed at stage 1 or 2, in line with England (55.3%) but below the 75.0% national ambition by 2028 (requiring about 2,270 extra early-stage cases a year). PCN breast screening coverage is 54.7% (Manchester 59.3%, ICB 68.8%, England 69.9%). Cervical screening coverage (aged 25-49) is 64.6% across the PCN (Manchester 57.2%, ICB 65.9%, England 66.8%) and 56.3% at City Health Centre. Staging data describes the wider ICB system, not PCN performance. Screening shortfalls indicate an opportunity for practices to strengthen proactive identification and recall.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Manchester University NHS Foundation Trust achieved 72.8% on the cancer 62-day referral to treatment standard (standard 85.0%), against England (71.2%), NHS Greater Manchester Integrated Care Board (75.7%), Northern Care Alliance NHS Foundation Trust (78.6%), and Tameside and Glossop Integrated Care NHS Foundation Trust (76.8%). On the 28-day faster diagnosis standard, the trust reached 80.1% (standard 75.0%; ICB 79.5%, England 79.3%). For all diagnostic tests waiting 6+ weeks, the trust recorded 9.0%, below England (23.1%) and Northern Care Alliance NHS Foundation Trust (15.7%). Provider waits reflect acute capacity rather than PCN delivery.
| Pathways within standard (%) | Manchester | Northern Care Alliance | Tameside and Glossop Integrated Care | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 75.20 | 82.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 94.54 | 96.25 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 78.65 | 76.77 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Northern Care Alliance | Tameside and Glossop Integrated Care | England |
|---|---|---|---|---|
| MRI | 11.68 | 5.09 | 0.00 | 21.40 |
| CT | 14.66 | 4.10 | 0.18 | 9.92 |
| Echocardiography | 4.91 | 31.48 | 0.00 | 28.48 |
| Colonoscopy | 4.51 | 40.04 | 1.51 | 30.83 |
| Gastroscopy | 29.35 | 36.48 | 5.45 | 29.02 |
| All 15 DM01 tests | 8.98 | 15.71 | 0.80 | 23.14 |
| Community services activity | Manchester residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 96,995 | 573,310 |
| Referrals | 20,270 | 94,470 |
| Patients with a contact | 31,040 | 183,535 |
Community services (residents of Manchester), Jun 2026 (provisional). In June 2026 (provisional), 92,690 community care activities were recorded for Manchester residents in experimental Community Services Statistics. Adults aged 65+ accounted for 43.3% of borough residents' contacts (42,015 of 96,995 contacts). These provisional experimental counts represent submitting providers across the local authority district rather than unique patients or PCN-level service activity.
Practice variation and patient experience
Phone access spans 33.6 pp and vaccination achievement varies 84.1 pp across practices
In 2025/26, clinical QOF achievement reached 99.0% at Ancoats Urban Village Medical Practice and 100.0% at both New Islington Medical Centre and City Health Centre (England 97.1%). Conversely, vaccination achievement spanned 84.1 pp, from 15.9% at Ancoats Urban Village Medical Practice to 100.0% at City Health Centre (England 55.2%), reflecting substantial delivery variation.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Ancoats Urban | 93 | 27.3 | 83.4% | 76.7% | 91.9% |
| New Islington | 93 | 31.8 | 81.1% | 75.7% | 88.5% |
| City Health Centre | 71 | 4.3 | 49.8% | 66.9% | 73.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 measures trail England over three years, led by dementia registers
Across 25 compared measures, 15 trail England's three-year trajectory. Relative shortfalls concentrate in disease registers: dementia fell 8.1% (England +6.0%), learning disability fell 6.9% (England +5.4%), and stroke fell 5.6% (England +2.3%). Heart failure reviews also fell 4.5% (England +8.7%), though PCN completion remains 82.4% (England 78.5%). In contrast, 12-month reviews outpaced national gains for COPD (+16.4% vs England +2.8%) and asthma (+14.5% vs England +4.4%). Falling registers alongside stable review completion may reflect working-age list growth; age-stratified searches would test whether disease identification is keeping pace.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Heart failure reviews
Learning disability register
Stroke register
COPD register
COPD reviews
Asthma reviews
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Manchester (LAD) | Asset | PCN | Manchester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 2 (115 beds) | n/a | Schools (catchment) | 60 | n/a |
| Children's centres | 5 | 34 | Places of worship | 23 | 289 |
| Libraries | 2 | 16 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 9 | 68 | Primary academies | 3 | 50 |
| Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and prescribing recall
Across the 1,680 asthma register, 66.4% had a review in the last 12 months (Manchester 67.0%, England 65.7%), leaving 564 (about 560) unreviewed alongside 3,341 items per 1,000 aged 5–19 (England 1,488). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Age-stratified dementia and register audit
Dementia prevalence is 0.1% (39 patients) vs Manchester 0.4% and England 0.8% (unadjusted gap +134 to +302 across 43,533 patients), after falling 8.1% over three years (England +6.0%). For discussion: practices could run age-stratified clinical searches and cross-check care-home and social-care records to test for uncoded diagnoses. Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Option 3
Targeted childhood booster call and recall
At age 5, 4-in-1 coverage is 77.4% (ICB 80.5%, England 80.9%), 17.6 pp below the 95.0% target (cohort 31); 24-month MMR1 is 83.0% (England 88.3%) and 12-month 6-in-1 is 85.7% (England 91.0%). Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Age-stratified clinical audit (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI blood pressure recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster call and recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and prescribing recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Age-stratified dementia and register audit (p12) | Dementia register · Dementia: QOF prevalence · Learning disability: QOF prevalence | 66.7% diagnosis ambition · 95% care plan 2027 · 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Option 3 · Targeted childhood booster call and recall (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at 24 months · 6-in-1 coverage at 12 months | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
